Literature DB >> 24872117

Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation.

Alyssa Reiffel Golas1, Tatiana Boyko, Theodore H Schwartz, Philip E Stieg, John A Boockvar, Jason A Spector.   

Abstract

Neurosurgical craniotomy, craniectomy, or other trans-galeal interventions are performed for a variety of indications, including the resection of benign or malignant tumors, hematoma evacuation, and for the management of intractable seizure disorders. Despite an overall low complication rate of intervention, wound healing complications such as dehiscence, surgical site infection, and cerebrospinal fluid leak are not uncommon. A retrospective review was performed of all patients who underwent scalp incision closure at a single institution by a single plastic surgeon between 2006 and 2013. Sixty patients (83 procedures) were included in the study. Fifty-seven patients (95.0 %) underwent previous craniotomy, craniectomy, or other trans-galeal procedure. Of the total 60 patients, 35 patients received preoperative radiation. Sixteen patients received bevacizumab prior to their index case, while 12 received bevacizumab postoperatively. Ten patients (16.7 %) required additional plastic surgical intervention for wound complications after their index plastic surgery procedure. Plastic surgery was consulted prophylactically in 34 patients (38 procedures). When plastic surgery was consulted prophylactically, 4 patients (11.8 %) required further wound revision. None of the 14 patients who underwent prophylactic plastic surgery closure for previous scalp incision, preoperative bevacizumab, and XRT administration required re-intervention. Plastic surgery closure of complex scalp incisions reduces the incidence of wound complications among patients who underwent previous neurosurgical intervention, XRT administration, and preoperative bevacizumab administration. This is particularly true when plastic surgery closure is performed "prophylactically." Further collaboration between the neurosurgical and plastic surgery teams is therefore warranted, particularly in the setting of these high-risk cases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24872117     DOI: 10.1007/s11060-014-1482-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Incidence, risk factors and management of delayed wound dehiscence after craniotomy for tumor resection.

Authors:  Kaveh Barami; Rui Fernandes
Journal:  J Clin Neurosci       Date:  2012-03-03       Impact factor: 1.961

Review 2.  Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.

Authors:  Debashish Bose; Funda Meric-Bernstam; Wayne Hofstetter; David A Reardon; Keith T Flaherty; Lee M Ellis
Journal:  Lancet Oncol       Date:  2010-02-18       Impact factor: 41.316

3.  Marked reduction in wound complication rates following decompressive hemicraniectomy with an improved operative closure technique.

Authors:  Michael E Sughrue; Orin G Bloch; Geoffrey T Manley; Shirley I Stiver
Journal:  J Clin Neurosci       Date:  2011-07-12       Impact factor: 1.961

4.  Management of a complex scalp defect.

Authors: 
Journal:  Plast Reconstr Surg       Date:  2008-08       Impact factor: 4.730

5.  Impact of bevacizumab chemotherapy on craniotomy wound healing.

Authors:  Aaron J Clark; Nicholas A Butowski; Susan M Chang; Michael D Prados; Jennifer Clarke; Mei-Yin C Polley; Michael E Sughrue; Michael W McDermott; Andrew T Parsa; Mitchel S Berger; Manish K Aghi
Journal:  J Neurosurg       Date:  2010-12-10       Impact factor: 5.115

Review 6.  Management of postneurosurgical bone flap loss caused by infection.

Authors:  Steffen Baumeister; Alberto Peek; Allen Friedman; L Scott Levin; Jeffrey R Marcus
Journal:  Plast Reconstr Surg       Date:  2008-12       Impact factor: 4.730

7.  Surgical management of radiated scalp in patients with recurrent glioma.

Authors:  S Nair; G Giannakopoulos; M Granick; M Solomon; T McCormack; P Black
Journal:  Neurosurgery       Date:  1994-01       Impact factor: 4.654

Review 8.  Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon.

Authors:  Ketan Sharma; Jeffrey R Marcus
Journal:  Ann Plast Surg       Date:  2013-10       Impact factor: 1.539

9.  Factors affecting graft infection after cranioplasty.

Authors:  Yu-Kai Cheng; Hsu-Huei Weng; Jen-Tsung Yang; Ming-Hsueh Lee; Ting-Chung Wang; Chen-Nen Chang
Journal:  J Clin Neurosci       Date:  2008-07-25       Impact factor: 1.961

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

View more
  2 in total

Review 1.  Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.

Authors:  Brandyn A Castro; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2014-12       Impact factor: 4.047

2.  The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

Authors:  Harry D Bear; Gong Tang; Priya Rastogi; Charles E Geyer; Christine K Zoon; Kelley M Kidwell; André Robidoux; Luis Baez-Diaz; Adam M Brufsky; Rita S Mehta; Louis Fehrenbacher; James A Young; Francis M Senecal; Rakesh Gaur; Richard G Margolese; Paul T Adams; Howard M Gross; Joseph P Costantino; Soonmyung Paik; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2016-11-18       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.